Experience with Prolift Mesh System for Correction of Uterovaginal Prolapse: Analysis of 149 Cases

Abstract

Objective:

The objective of this retrospective chart review was to assess the feasibility, potential complications, safety, and efficacy of the Prolift^® system to correct uterovaginal prolapse.

Materials and Methods:

Subjects treated with the original Gynecare Prolift^® Mesh System (Somerville, NJ) between September 2005 and March 2009 were analyzed retrospectively. Outcomes assessed included intra- and postoperative complications and anatomical success.

Results:

Women (149 subjects; ages: 65.2 ± 10.9 years; body mass index: 29.47 ± 5.65 kg/m²) were treated for pelvic organ prolapse (POP) using the Prolift system. Forty-eight anterior Prolift, 42 posterior Prolift, and 59 combined (total) Prolift mesh surgeries were performed in subjects with stage II or greater degrees of POP. Mean follow-up was 18.6 months. Composite surgical success was 80.5%. Pure anatomical success (Pelvic Organ Prolapse–Quantification stage < II) was 89.6%. Mean operative time was 125 ± 41 minutes. Mean intraoperative blood loss was 111.5 mL. Adverse events were minimal and included 1 (0.07%) hematoma, 3 (2%) blood losses >500 mL, 20 (13.4%) mesh exposures, and of 34 subjects with dyspareunia (14.7%), 5 reporting de novo dyspareunia.

Conclusions:

The Prolift mesh reconstruction procedure is safe and effective, with minimal postoperative morbidity.